Dongping Yao, Dongtao Liu, Ruijie Luo, Siyan He, Lang Bai, Yang Yang, Jialin Ma, Xi He, Mingxing Hu, Haozhong Luo, Bin Chen, Feng Liu, Tinghong Ye, Xiangrong Song, Zhongwei Zhang, Yongmei Xie
Tenofovir (TFV), an acyclic nucleoside analog, exhibits potent anti-HBV activity. However, poor bioavailability, nephrotoxicity and bone toxicity limit its further clinical application. In this work, a novel tenofovir-loaded glycyrrhetinic acidmodified cationic liposome (TGCL) was prepared for targeted therapy of HBV. The TGCL had an average particle size of 107.39 ± 1.21 nm and an entrapment efficiency of 89.83 ± 2.70% with a positive zeta potential of 37.63 ± 1.22 mV. The results of in vitro indicated that the inhibitory effects on HBsAg, HBeAg and HBV cccDNA of TGCL in HepG2...
October 1, 2020: Journal of Biomedical Nanotechnology